Literature DB >> 23580412

Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett's esophagus with early neoplasia: a prospective multicenter study.

F G I van Vilsteren1, L Alvarez Herrero, R E Pouw, D Schrijnders, C M T Sondermeijer, R Bisschops, J M Esteban, A Meining, H Neuhaus, A Parra-Blanco, O Pech, K Ragunath, B Rembacken, B E Schenk, M Visser, F J W ten Kate, S L Meijer, J B Reitsma, B L A M Weusten, E J Schoon, J J G H M Bergman.   

Abstract

BACKGROUND AND STUDY AIMS: Radiofrequency ablation (RFA) is safe and effective for the eradication of neoplastic Barrett's esophagus; however, occasionally there is minimal regression after initial circumferential balloon-based RFA (c-RFA). This study aimed to identify predictive factors for a poor response 3 months after c-RFA, and to relate the percentage regression at 3 months to the final treatment outcome.
METHODS: We included consecutive patients from 14 centers who underwent c-RFA for high grade dysplasia at worst. Patient and treatment characteristics were registered prospectively. "Poor initial response" was defined as < 50 % regression of the Barrett's esophagus 3 months after c-RFA, graded by two expert endoscopists using endoscopic images. Predictors of initial response were identified through logistic regression analysis.
RESULTS: There were 278 patients included (median Barrett's segment C4M6). In poor initial responders (n = 36; 13 %), complete response for neoplasia (CR-neoplasia) was ultimately achieved in 86 % (vs. 98 % in good responders; P < 0.01) and complete response for intestinal metaplasia (CR-IM) in 66 % (vs. 95 %; P < 0.01). Poor responders required 13 months treatment (vs. 7 months; P < 0.01) for a median of four RFA sessions (vs. three; P < 0.01). We identified four independent baseline predictors of poor response: active reflux esophagitis (odds ratio [OR] 37.4; 95 % confidence interval [CI] 3.2 - 433.2); endoscopic resection scar regeneration with Barrett's epithelium (OR 4.7; 95 %CI 1.1 - 20.0); esophageal narrowing pre-RFA (OR 3.9; 95 %CI 1.0 - 15.1); and years of neoplasia pre-RFA (OR 1.2; 95 %CI 1.0 - 1.4).
CONCLUSIONS: Patients with a poor initial response to c-RFA have a lower ultimate success rate for CR-neoplasia/CR-IM, require more treatment sessions, and a longer treatment period. A poor initial response to c-RFA occurs more frequently in patients who regenerate their endoscopic resection scar with Barrett's epithelium, and those with ongoing reflux esophagitis, neoplasia in Barrett's esophagus for a longer time, or a narrow esophagus. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 23580412     DOI: 10.1055/s-0032-1326423

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  18 in total

1.  Changes in gene expression of neo-squamous mucosa after endoscopic treatment for dysplastic Barrett's esophagus and intramucosal adenocarcinoma.

Authors:  Angelique Levert-Mignon; Michael J Bourke; Sarah J Lord; Andrew C Taylor; Antony R Wettstein; Melanie Edwards; Natalia K Botelho; Rebecca Sonson; Chatura Jayasekera; Oliver M Fisher; Melissa L Thomas; Finlay Macrae; Damian J Hussey; David I Watson; Reginald V Lord
Journal:  United European Gastroenterol J       Date:  2016-07-07       Impact factor: 4.623

Review 2.  Endoscopic treatments for dysplastic Barrett's esophagus: resection, ablation, what else?

Authors:  Charumathi Raghu Subramanian; George Triadafilopoulos
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

Review 3.  Post-ablation surveillance in Barrett's esophagus: A review of the literature.

Authors:  Matthew W Stier; Vani J Konda; John Hart; Irving Waxman
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

Review 4.  Radiofrequency ablation for Barrett's dysplasia: past, present and the future?

Authors:  Rehan Haidry; Laurence Lovat; Prateek Sharma
Journal:  Curr Gastroenterol Rep       Date:  2015-03

Review 5.  Ablation Therapy for Barrett's Esophagus: New Rules for Changing Times.

Authors:  Nour Hamade; Prateek Sharma
Journal:  Curr Gastroenterol Rep       Date:  2017-08-17

6.  Effectiveness of focal vs. balloon radiofrequency ablation devices in the treatment of Barrett's esophagus.

Authors:  Jesica Brown; Benjamin Alsop; Neil Gupta; Daniel C Buckles; Mojtaba S Olyaee; Prashanth Vennalaganti; Vijay Naag Kanakadandi; Shreyas Saligram; Prateek Sharma
Journal:  United European Gastroenterol J       Date:  2015-07-03       Impact factor: 4.623

7.  Effects of preceding endoscopic mucosal resection on the efficacy and safety of radiofrequency ablation for treatment of Barrett's esophagus: results from the United States Radiofrequency Ablation Registry.

Authors:  N Li; S Pasricha; W J Bulsiewicz; R E Pruitt; S Komanduri; H C Wolfsen; G W Chmielewski; F S Corbett; K J Chang; N J Shaheen
Journal:  Dis Esophagus       Date:  2015-06-30       Impact factor: 3.429

Review 8.  Mucosal Ablation in Patients with Barrett's Esophagus: Fry or Freeze?

Authors:  Kavel Visrodia; Liam Zakko; Kenneth K Wang
Journal:  Dig Dis Sci       Date:  2018-08       Impact factor: 3.199

Review 9.  Update on ablation for Barrett's esophagus.

Authors:  Gary W Falk
Journal:  Curr Gastroenterol Rep       Date:  2014-01

10.  Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry.

Authors:  R J Haidry; M A Butt; J M Dunn; A Gupta; G Lipman; H L Smart; P Bhandari; L Smith; R Willert; G Fullarton; M Di Pietro; C Gordon; I Penman; H Barr; P Patel; N Kapoor; J Hoare; R Narayanasamy; Y Ang; A Veitch; K Ragunath; M Novelli; L B Lovat
Journal:  Gut       Date:  2014-12-24       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.